Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes

Oncology Reports

Volumn 17, Issue 5, 2007, Pages 1249-1257

  Pajtasz Piasecka, Elzbieta ^a   Rossowska, Joanna ^a   Szyda, Anna ^a   Krawczenko, Agnieszka ^a   Dus, Danuta ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

IFN production; Interleukin 12 genes transduced JAWS II mouse dendritic cells; Mouse murine colon carcinoma; T cell cytotoxicity

Indexed keywords

CANCER VACCINE; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; C57BL MOUSE; CD8+ T LYMPHOCYTE; COLON TUMOR; DENDRITIC CELL; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; METHODOLOGY; MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DENDRITIC CELLS; GREEN FLUORESCENT PROTEINS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548573206     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.5.1249     Document Type: Article

References (33)

1. Colombo MP and Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168, 2002. (Pubitemid 34229390)
2. Trinchieri G: Interleukin-12: cytokine at the interface of inflammation and immunity. Adv Immunol 70: 83-243, 1998.
3. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146, 2003.
4. Indrová M, Reinis M, Bubeník J, Jandlová T, Bieblová J, Vonka V and Velek J: Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects. Folia Biol (Praha) 50: 184-193, 2004. (Pubitemid 40220742)
5. Huttner KG, Breuer SK, Paul P, Majdic O, Heitger A and Felzmann T: Generation of potent anti-tumor immunity in by interleukin-12-secreting dendritic cells. Cancer Immunol Immunother 54: 67-77, 2005. (Pubitemid 40064487)
6. Lasek W, Feleszko W, Golab J, Stoklosa T, Marczak M, Dabrowska A, Malejczyk M and Jakóbisiak M: Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor a in mice. Cancer Immunol Immunother 45: 100-108, 1997. (Pubitemid 27497685)
7. Ribas A, Butterfield LH, Glaspu J and Economou JS: Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther 2: 57-78, 2002.
8. Lanzavecchia A and Sallusto F: The instructive role of dendiritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 13: 291-298, 2001. (Pubitemid 32537700)
9. Gunzer M, Jänich S, Varga G and Grabbe S: Dendritic cells and tumor immunity. Semin Immunol 13: 291-302, 2001. (Pubitemid 32744580)
10. Indrova M, Mendoza L, Reinis M, Vonka V, Smahel M, Nemeckowá S, Jandlowá T and Bubenik J: Bone marrow dendritic cell-based anticancer vaccines. Adv Exp Med Biol 445: 355-358, 2001. (Pubitemid 34110443)
11. Kotera Y, Shimizu K and Mule JJ: Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 61: 8105-8109, 2001. (Pubitemid 33091598)
12. Melero I, Duarte M, Ruiz J, Sangro B, Galofre IC, Mazzolini G, Bustos M, Qian C and Prieto J: Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 6: 1779-1784, 1999. (Pubitemid 29485955)
13. Mendoza L, Indrova M, Hájková R, Reinis M, Smahel M, Vonka V, Bubenik J and Jandlowá T: Peritumoral administration of antigen-unstimulated bone marrow-derived dendritic cells inhibits tumour growth. Folia Biol (Praha) 46: 91-97, 2000. (Pubitemid 30456067)
14. Nencioni A and Brossart P: Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells 22: 501-513, 2004. (Pubitemid 39014566)
15. Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M and Hayashi N: Administration of interleukin-12 enhances the therapeutic efficacy of dendritidc cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 61: 7563-7567, 2001. (Pubitemid 32995049)
16. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, Hantschel M, Brugger W, Schroder S, Horger MS, Kanz L and Brossart P: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66: 5910-5918, 2006. (Pubitemid 43927146)
17. Akiyama Y, Watanabe M, Maruyama K, Ruscetti FW, Wiltrout RH and Yamaguchi K: Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines. Gene Ther 7: 2113-2121, 2000. (Pubitemid 32118080)
18. + cell-derived dendritic cells. Int J Oncol 21: 509-514, 2002.
19. Gambotto A, Cicinnati VR and Robbins PD: Genetic engineering of dendritic cells. In: Dendritic Cells Biology and Clinical Applications. Lotze MT and Thomson AW (eds). 2nd edition. 2001
20. Indrová M, Bubeník J, Mikysková R, Mendoza L, Símová J, Bieblová J, Jandlová T, Jinoch P, Smahel M, Vonka V and Pajtasz-Piasecka E: Chemoimmunotherapy in mice carrying HPV-16 associated, MHC class I and MHC class I tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int J Oncol 22: 691-695, 2003.
21. Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K and Yamaue H: The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Int J Oncol 28: 947-953, 2006.
22. Nishioka Y, Hirao M, Robbins PD, Lotze MT and Tahara H: Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12 of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 59: 4035-4041, 1999. (Pubitemid 29393574)
23. Kusnierczyk H, Pajtasz-Piasecka E and Radzikowski C: Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and interleukin-2-secreting cells in a mouse colon cancer model. Med Oncol 16: 267-278, 1999. (Pubitemid 30055716)
24. Pajtasz-Piasecka E, Glazman-Kusnierczyk H, Salwa J, Konarski L and Radzikowski C: Growth inhibition of transplantable tumors in mice by mIL-2-secreting murine plasmocytoma cells used alone or in combination with a cytostatic agent. Arch Immunol Ther Exp 43: 281-292, 1995. (Pubitemid 26066891)
25. Pajtasz-Piasecka E, Kusnierczyk H, Krawczyk K, Piasecki E, Elas M and Radzikowski C: The effects of peritumoral therapeutic vaccination with IL-2-secreting cells on growth of MC38 colon tumors, local NO production and sentinel lymph node cells activation. Adv Exp Med Biol 495: 385-388, 2001. (Pubitemid 34106964)
26. Pajtasz-Piasecka E, Szyda A, Rossowska J, Krawczenko A, Indrova M, Grabarczyk P, Wysocki P, Mackiewicz A and Dus D: Loss of tumorigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes. Folia Biol (Praha) 50: 7-14, 2004. (Pubitemid 38418118)
27. Szyda A, Pajtasz-Piasecka E, Krawczenko A, Grabarczyk P, Wysocki P, Kozlak J, Paprocka M, Mackiewicz A and Dus D: Mouse colon carcinoma MC38 cell line for rapid and accurate titration of amphotropic retroviral vector. Polish J Environ Studies 14 (Suppl II): 790-794, 2005.
28. Sift 2003, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R and Gnant M: Dendritic cell-based vaccination in solid cancer. J Clin Oncol 21: 135-142, 2003.
29. Brossart P, Goldrath AW, Butz EA, Martin S and Bevan MJ: Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 158: 3270-3276, 1997. (Pubitemid 127484043)
30. Butz EA and Bevan MJ: Differential presentation of the same MHC class I epitopes by fibroblasts and dendritic cells. J Immunol 160: 2139-2144, 1998. (Pubitemid 28119892)
31. Steinman RM and Dhodapkar M: Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94: 459-473, 2001. (Pubitemid 32979535)
32. Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH and Economou JS: Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol 172: 4762-4769, 2004. (Pubitemid 38456397)
33. Schulz E, Berger T and Shuler G: Immunotherapy and dendritic cells. Enhancer Biother Cancer 2: 2-7, 2004. Technology Technology